Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer
Hyun-Seock Shin, Juwhan Choi, Jinhwan Lee, Sung Yong Lee
Cancer Res Treat. 2022;54(2):458-468.   Published online 2021 Sep 10     DOI: https://doi.org/10.4143/crt.2021.425
Citations to this article as recorded by Crossref logo
Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma
Hikaru Nanamori, Yu Sawada
International Journal of Molecular Sciences.2022; 23(3): 1119.     CrossRef
Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer
Shuo Yang, Yang Huang, Qi Zhao
Frontiers in Immunology.2022;[Epub]     CrossRef
Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance
Hyein Jo, Kyeonghee Shim, Dooil Jeoung
International Journal of Molecular Sciences.2022; 23(17): 9592.     CrossRef
Immunomodulatory properties of HDAC6 inhibitors in cancer diseases: New chances for sophisticated drug design and treatment optimization
Bernhard Biersack, Bianca Nitzsche, Michael Höpfner
Seminars in Cell & Developmental Biology.2022;[Epub]     CrossRef
Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review)
Xiaoran Ma, Jibiao Wu, Bin Wang, Cun Liu, Lijuan Liu, Changgang Sun
International Journal of Oncology.2022;[Epub]     CrossRef